TuHURA Biosciences raises $15.6 million in equity financing

TuHURA Biosciences Inc. (NASDAQ: HURA) announced a $15.6 million equity financing transaction to fund multiple development programs across its cancer immunotherapy portfolio.

The Tampa-based company is conducting a Phase 3 trial of its lead drug IFx-2.0 as adjunctive therapy with Keytruda for advanced and metastatic Merkel cell carcinoma under a Special Protocol Assessment agreement with the FDA. The company expects to complete enrollment for this study in the fourth quarter of 2026.

TuHURA held a symposium on December 5 focused on its VISTA inhibiting antibody TBS-2025 for acute myeloid leukemia treatment. The company plans to seek FDA clearance to initiate a randomized Phase 2 trial comparing a menin inhibitor alone versus a menin inhibitor combined with TBS-2025 in NPM1 mutated relapsed/refractory AML patients.

At the recent American Society of Hematology Annual Meeting, the company presented data on its Delta Opioid Receptor technology for developing antibody drug conjugates targeting immune-suppressing cells in the tumor microenvironment.

"We look forward in 2026 to the expected completion of enrollment for our Phase 3 study of IFx-2.0 in MCC, and anticipate receiving FDA clearance to initiate our randomized Phase 2 trial," said Dr. James Bianco, President and Chief Executive Officer.

The financing follows a previous $15 million PIPE financing and warrant exercise completed in June 2025. TuHURA completed a merger with Kineta Inc. in June 2025, acquiring the TBS-2025 asset.

The company will host a conference call on December 11 at 8:30 a.m. Eastern Time to discuss the corporate update and recent financing.

You May Also Be Interested In

• Deutsche Bank cuts winter airline capacity forecasts as fuel costs remain high
• Evolution Metals plans 750 MW power expansion at South Korea facility
• Eos Energy to move battery manufacturing to Thorn Hill facility